GGrantIndex
Sort

15,440 grants matching organoids

Identifying Combination Therapies in Ovarian Tumors using High Throughput Dynamic BH3 Profiling

$69,802
Kelley McQueeney · Dana-Farber Cancer Inst · F32 · FY2022 · CA

ST6Gal-1 contributes to pancreatic cancer initiation by promoting pancreatitis-induced acinar to ductal metaplasia

$69,802
Michael Marciel · University Of Alabama At Birmingham · F32 · FY2022 · CA

Epigenetic regulators of subtype plasticity in bladder cancer

$69,802
John Robert Christin · Columbia University Health Sciences · F32 · FY2022 · CA

Investigating Mechanisms of RBM20 Liquid-liquid Phase Separation Driving Cardiomyocyte Physiology and Dilated Cardiomyopathy

$69,802
Aidan Mandy Fenix · University Of Washington · F32 · FY2022 · HL

Enhancer-targeted correction of haploinsufficient autism risk genes

$69,802
George Tsun-Te Chen · University Of California Los Angeles · F32 · FY2022 · MH

Synthetic approaches to study cell polarity related kidney defects

$69,802
Louis Skjei Prahl · University Of Pennsylvania · F32 · FY2022 · DK

Modeling gene regulatory mechanisms contributing to the evolution of the human cerebral cortex

$69,802
Mary Baumgartner · Yale University · F32 · FY2022 · HD

Generation of Tay Sachs cell models and assay approaches for small molecule discovery

$69,740
Mark Henderson · National Center For Advancing Translational Sciences · ZIA · FY2025 · TR

LETSSGo: Lymphoma-on-chip Engineered Technology for Single-Organoid Sequencing and Genomics

$69,615
Ankur Singh · Cornell University · R33 · FY2018 · CA

Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy

$69,518
David Gius · University Of Texas Hlth Science Center · R01 · FY2022 · CA

Mechanisms of microRNA dysregulation in Fragile X Syndrome

$69,500
Adam Kosti · Emory University · F32 · FY2023 · MH

Epigenetic regulation of lineage specification in colon epithelial cells

$69,500
Anne R. Meyer · University Of Colorado Denver · F32 · FY2023 · DK

Epigenetic Drug Regimens for Homologous Recombination Proficient Ovarian Cancer - Diversity Supplement

$69,487
Dineo Khabele · Washington University · R01 · FY2022 · CA

Combining Irreversible Electroporation with Immunotherapy for the Systemic Treatment of Pancreatic Cancer

$69,324
Rebekah White · University Of California, San Diego · R01 · FY2024 · CA

The Role of the Epigenetic Regulator UHRF1 in Colon Tumorigenesis

$69,306
Alison Ann Lanctot Chomiak · Van Andel Research Institute · F32 · FY2020 · CA

Effect of Pre- and Peri-Implantation Zika Virus Infection on Fetal Development

$69,306
Lauretta A. Lacko · Weill Medical Coll Of Cornell Univ · F32 · FY2020 · HD

Identification of a Wnt/ Beta-catenin responsive adult lung epithelial progenitor cell for tissue repair in chronic lung disease

$69,306
Yan Hu · University Of Colorado Denver · F32 · FY2020 · HL

Development and Function of Biliary Tuft Cells

$69,306
Claire E O'Leary · University Of California, San Francisco · F32 · FY2020 · DK

Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer

$69,142
Cullen Mitsuo Taniguchi · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Pilot Project 1: Combination of Viroimmunotherapy and Microbiota Modulation to Treat Gastric Cancer

$69,122
Candelaria Gomez-Manzano · University Of Tx Md Anderson Can Ctr · U54 · FY2020 · CA

Investigation of the role of X-Linked Inhibitor of Apoptosis Protein in African American IBC-derived

$68,947
Steven R Patierno · Duke University · P20 · FY2019 · CA

A premalignant chronology of cell-state variability in basal-like breast cancer

$68,912
Kevin A Janes · University Of Virginia · R01 · FY2024 · CA

Functions of specialized pulmonary endothelial cell types in regeneration of the lung

$68,890
Terren Kathryn Niethamer · University Of Pennsylvania · F32 · FY2021 · HL

Basic Science Core C

$68,836
Jason T Kimata · Baylor College Of Medicine · P30 · FY2025 · AI

Detection of Colorectal Cancer Adaptive Mutability May Justify Combination of Targeted- and Immune-Therapies

$68,770
Timothy J Yeatman · University Of Utah · R21 · FY2021 · CA